In last night’s announcement, Affymax said it was taking these steps “to focus the company’s resources on the ongoing investigation of reported hypersensitivity reactions” to its leading drug. The company was forced to recall its anemia drug, Omontys, in February after 50 patients developed severe allergic reactions to the injectable drug and five people died. Affymax really has no other drug pipeline available to take up the slack from the recall, which may turn out to be permanent. Japan’s Takeda Pharmaceutical Co. is a partner with Affymax in making and distributing Omontys.
Among the strategic alternatives the company is considering are further restructuring, a “wind-down of operations, or even bankruptcy proceedings.”
Shares of Affymax are down more than 56% in premarket trading this morning, at $1.27, well below the 52-week range of $2.26 to $27.74.
Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
